German-based Wacker Chemie buys Dutch biopharma site for undisclosed price

Handshake business deal executives
Munich-based Wacker Chemie purchased a Dutch biopharma manufacturing site and associated business from SynCo Bio Luxembourg for an undisclosed price. (Pixabay)

Wacker Chemie, a chemical company based in Munich, purchased a Dutch biopharma manufacturing site and associated business from SynCo Bio Luxembourg for an undisclosed price.

Wacker said it plans to keep all of SynCo’s 110 employees. The plant operates a pair of fermentation lines with current capacities of 1,500 and 270 liters that manufacture microbial-derived biopharmaceuticals for clinical testing and the commercial market. There is also a line of  single-use fermenters and a “fill and finish” facility.

“Expanding our production capacity strengthens our market position sustainably,” Gerhard Schmid, president of Wacker Biosolutions, said in a statement. “The additional fermentation lines double our current capacity, which increases our ability to produce key pharmaceuticals cost effectively, using advanced microbial techniques.”

Live microbial products are seen in the industry as a promising new class of actives that offer innovative therapies for serious illnesses and new vaccines.

Suggested Articles

GBA offers Brexit escape, Merck and Just - Evotech to share production space, GSK ointment line in Bangladesh may reopen and more news of note.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.